About Acorda Therapeutics
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson's disease, chronic post-stroke walking deficits and migraine.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: ACOR
- CUSIP: 00484M10
- Previous Close: $25.30
- 50 Day Moving Average: $21.40
- 200 Day Moving Average: $21.73
- 52-Week Range: $45,500,000.00 - $16.40
- Trailing P/E Ratio: 101.20
- Foreward P/E Ratio: 18.88
- P/E Growth: 0.85
- Market Cap: $1166.68B
- Outstanding Shares: 45,500,000
- Beta: 1.53
- Net Margins: -4.38%
- Return on Equity: -1.66%
- Return on Assets: -0.88%
Companies Related to Acorda Therapeutics:
- Debt-to-Equity Ratio: 0.45%
- Current Ratio: 2.01%
- Quick Ratio: 1.67%
What is Acorda Therapeutics' stock symbol?
Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."
Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2017?
9 equities research analysts have issued 12 month price targets for Acorda Therapeutics' shares. Their predictions range from $22.00 to $60.00. On average, they expect Acorda Therapeutics' share price to reach $34.22 in the next twelve months.
When will Acorda Therapeutics announce their earnings?
Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
What are analysts saying about Acorda Therapeutics stock?
Here are some recent quotes from research analysts about Acorda Therapeutics stock:
According to Zacks Investment Research, "Acorda’s flagship product Ampyra has been doing well and is expected to continue doing so. Promotional efforts and increasing awareness should help sales growth. Meanwhile, Acorda continues to work on expanding its pipeline by entering into deals and pursuing acquisitions. The company’s share price outperformed the industry in past three months. However, with Ampyra facing several patent challenges, focus will remain on the company’s pipeline development efforts and ability to bring new products to market. Moreover, Acorda recently discontinued the development of Ampyra for post-stroke walking difficulties, which hurt investor sentiment. Estimates have remained stable lately ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters." (1/23/2017)
Cowen and Company analysts commented, "ACOR released Q4 Ampyra revenue and provided 2017 Ampyra guidance, both just." (1/9/2017)
Who owns Acorda Therapeutics stock?
Acorda Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.99%), State Street Corp (3.58%), Dimensional Fund Advisors LP (3.27%), Perceptive Advisors LLC (1.56%), Broadfin Capital LLC (1.40%) and Armistice Capital LLC (0.93%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Andrew Blight, David Lawrence, Enrique J Carrazana, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Michael W Rogers, Richard P Batycky, Ron Cohen and Steven M Rauscher.
Who sold Acorda Therapeutics stock? Who is selling Acorda Therapeutics stock?
Acorda Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management, Armistice Capital LLC, Renaissance Technologies LLC, Guggenheim Capital LLC, Teachers Retirement System of The State of Kentucky, FMR LLC and Martingale Asset Management L P. Company insiders that have sold Acorda Therapeutics stock in the last year include Andrew A Hindman, David Lawrence, Jane Wasman, Lorin Randall, Richard P Batycky, Ron Cohen and Steven M Rauscher.
Who bought Acorda Therapeutics stock? Who is buying Acorda Therapeutics stock?
Acorda Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, State Street Corp, Dimensional Fund Advisors LP, Two Sigma Investments LP, Russell Investments Group Ltd., A.R.T. Advisors LLC, Broadfin Capital LLC and Tudor Investment Corp Et Al.
How do I buy Acorda Therapeutics stock?
Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Acorda Therapeutics stock cost?
One share of Acorda Therapeutics stock can currently be purchased for approximately $25.30.